Skip to content
  • Report Harm
  • Newsletter
  • Shop
  • Media Kit
Facebook Linkedin Twitter RSS YouTube Instagram
Benzodiazepine Information Coalition
  • About BenzodiazepinesExpand
    • Benzo BasicsExpand
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • PrescribingExpand
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing RisksExpand
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • DeprescribingExpand
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing RisksExpand
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special PopulationsExpand
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About UsExpand
    • Media Kit
    • VolunteerExpand
      • Media Interview List Registration
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
  • Our Impact
  • ResourcesExpand
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Benzodiazepine Cooperative Providers
  • Blog
  • Contact UsExpand
    • Receive Our Newsletter
  • Donate
Donate
Facebook Linkedin Twitter Phone RSS Instagram
Benzodiazepine Information Coalition

Low Dose Benzodiazepines

The pharmaceutical industry has a long history of romanticizing language. When the word ‘withdrawal’ evoked negative feelings in relation to psychiatric drugs, the term ‘discontinuation syndrome’ was substituted. The same is true with benzodiazepine dosing. Patients are often told that they are on a tiny or “low dose” of a benzodiazepine. This misleads patients in two ways:

  1. Benzodiazepines are not available in truly low doses. The doses may sound low, but, when equated to other benzodiazepines, they are not.
  2. That “low” benzodiazepine doses are somehow safer. Any dose can create physical dependence and withdrawal syndromes if used consecutively for more than a few days to a few weeks.

In the 1970s, when patients, physicians and legislators attempted to hold the makers of Valium accountable for the harm they created, the term ‘anxiolytics’ was introduced. This new term described a newer crop of benzodiazepines—Xanax, Ativan, Klonopin—that were more potent but carried smaller dosage labels, deceiving patients into thinking that they were taking a smaller amount. In reality, they were actually taking a dose as much as 20 times more potent than an equivalent dose of Valium. 

In benzodiazepine studies and medical literature the term “low dose” is subjective, or often used without any quantifying amount. There is no agreement on the exact range of dosages intended by this term and seems to be used in an arbitrary fashion.

Because certain benzodiazepines are dosed in amounts that may sound “low dose,” such as lorazepam (Ativan), clonazepam (Klonopin) and alprazolam (Xanax) the dosages can be misleading. For example, 0.5 milligrams of Klonopin, 1 milligram of Ativan and 0.5 mg of Xanax are equivalent to 10 milligrams of Valium. This means that 0.5 mg of Klonopin may likely require a lengthy taper for safe cessation. (To covert a benzodiazepine dose using the Ashton Equivalence click here).

Relative potency

The three most potent benzodiazepines (or ‘anxiolytics’) are alprazolam (Xanax), clonazepam (Klonopin) and lorazepam (Ativan) which are 10–20 times more potent than diazepam.

So while 0.5mg of Xanax (alprazolam) sounds like a “small dose” or “low dose,” compared to someone taking 10mg of Valium (diazepam), it is not; they are, in fact, equivalent. Someone taking 4mg of clonazepam (Klonopin), which is the maximum recommended dosage for panic disorder, may have no idea that they are being prescribed the equivalent of 80mg of Valium! Four certainly sounds “small” compared to eighty; in reality, they are essentially the same thing (or equivalent).

Low Doses Are Not Safe Doses

According to Professor Heather Ashton, a medical expert on benzodiazepines and withdrawal, a safe dose to stop Valium after approximately a 40 week (or longer) taper is 0.5 -1 mg of Valium (or less), which is 0.03 mg of Klonopin or Xanax. It is important to note the lowest doses available for Klonopin, Ativan and Xanax are at least 10-20x more potent than the safest, lowest recommended dose to stop a benzodiazepine. 

The term low dose can be very misleading to patients. There are two possible common outcomes to a low dose that are concerning:

  1. The development of tolerance to the “low dose” which may lead to withdrawal symptoms often mistaken as the return, worsening, of the patient’s underlying condition. It is frequently misdiagnosed as a new condition. This frequently results in prescribers increasing the dose and/or prescribing additional medications.
  2. Cessation, which can cause problems and disability when a benzodiazepine is taken at either a low dose or a higher dose. The feelings of security of believing one is on a low dose are often found to be false, and the patient ends up confused, on multiple medications believing they cannot be experiencing symptoms on such a low dose, or surprised to find out their low dose wasn’t that low at all. 

All patients deserve informed consent, regardless of the perception of the size of the dosage, because every dosage has the potential for tolerance, physical dependence and protracted injury.

Contact Us

Inquiries:
bic@benzoinfo.com

We do not offer any support services or guidance. See our resources for services and support.

Mailing Address:
1042 Ft. Union Blvd, PMB 1030
Midvale, Utah 84047

Support Us

We were formed to change the lack of knowledge in the public and the medical system. But we cannot do it alone. We rely solely on donations to operate. We are a 501(c)(3) tax exempt organization.

DONATE

Newsletter

Receive the latest benzodiazepine activism news, events and calls to action.

Notices

Benzodiazepine Information Coalition is a 501(c)3 tax exempt organization.

EIN: 81-3442343

Privacy Policy
Medical Disclaimer
Terms and Conditions
Free Charity Hosting by Kualo

Twitter Facebook Linkedin YouTube Instagram

© 2022 Benzodiazepine Information Coalition

Scroll to top
  • About Benzodiazepines
    • Benzo Basics
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Prescribing
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing Risks
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • Deprescribing
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing Risks
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special Populations
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About Us
    • Media Kit
    • Volunteer
      • Media Interview List Registration
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
  • Our Impact
  • Resources
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Benzodiazepine Cooperative Providers
  • Blog
  • Contact Us
    • Receive Our Newsletter
  • Donate
Search
Open toolbar

Accessibility Tools

  • Increase Text
  • Decrease Text
  • Grayscale
  • High Contrast
  • Negative Contrast
  • Light Background
  • Links Underline
  • Readable Font
  • Reset